Abstract
Ocriplasmin is currently the only approved pharmacologic agent for the release of vitreo-macular traction. Its success rate in releasing vitreo-macular traction under optimal conditions is about 40 %. Traction is present in a number of processes leading to macular disease, which suggests that its prophylactic release might have significant clinical relevance. Release of traction or vitreous adhesion in conditions such as macular edema from diabetes or retinal vein occlusion, vascular proliferation, or retinal degeneration or neovascularization can be considered under appropriate circumstances. To this end, the biology of the particular disease process must be considered. Partial release of the posterior hyaloid in pre-proliferative diabetic retinopathy may be associated with an increase risk of proliferation, while in macular edema, early intervention may be required for success.
A challenge will be the development of a treatment regimen that enhances the rate with which complete PVD is achieved either with a single or multiple injections or by combination with other pharmacologic agents. It will also be important to develop means of improving the visualization of the interface between the retina and vitreous. Specific scanning techniques and algorithms currently being developed for the OCT and new ultrasonographic probes are likely to facilitate such visualization and help in the diagnostic and therapeutic management of patients with diseases at the vitreoretinal interface.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aerts F, Noppen B, Fonteyn L et al (2012) Mechanism of inactivation of ocriplasmin in porcine vitreous. Biophys Chem 165–166:30–38. doi:10.1016/j.bpc.2012.03.002
Akiba J, Arzabe CW, Trempe CL (1990) Posterior vitreous detachment and neovascularization in diabetic retinopathy. Ophthalmology 97:889–891
Asami T, Wong SC, Mitchell PC et al (2012) A novel quadraport needle with improved intravitreal drug dispersion. Retina 32:1222–1225
Barak Y, Ihnen MA, Schaal S (2012) Spectral domain optical coherence tomography in the diagnosis and management of vitreoretinal interface pathologies. J Ophthalmol 2012:876472. doi:10.1155/2012/876472
Barteselli G, Bartsch DU, El-Emam S et al (2013) Combined depth imaging technique on spectral-domain optical coherence tomography. Am J Ophthalmol 155:727–732. doi:10.1016/j.ajo.2012.10.019
Boon C, Crama N, Klevering B et al (2008) Reflux after intravitreal injection of bevacizumab. Ophthalmology 115:1268
Chan CK, Wessels IF, Friedrichsen EJ (1995) Treatment of idiopathic macular holes by induced posterior vitreous detachment. Ophthalmology 102:757–767
De Croos FC, Toth CA, Folgar FA et al (2012) Characterization of vitreoretinal interface disorders using OCT in the interventional phase 3 trials of ocriplasmin. Invest Ophthalmol Vis Sci 53:6504–6511. doi:10.1167/iovs.12-10370
de Smet MD, Gandorfer A, Stalmans P et al (2009) Microplasmin intravitreal administration in patients with vitreomacular traction scheduled for vitrectomy: the MIVI I trial. Ophthalmology 116:1349–1355
de Smet MD, Gad El Kareem A, Zwinderman AH (2013) The vitreous, the retinal interface in ocular health and disease. Ophthalmologica in press. doi: 10.1159/000353447
de Smet MD, Jonckx B, Vanhove M et al (2012) Pharmacokinetics of ocriplasmin in vitreous. Invest Ophthalmol Vis Sci 53:8208–8213. doi:10.1167/iovs.12-10148
Falkner-Radler CI, Glittenberg C, Hagen S et al (2010) Spectral-domain optical coherence tomography for monitoring epiretinal membrane surgery. Ophthalmology 117:798–805. doi:10.1016/j.ophtha.2009.08.034
Faulborn J, Bowald S (1985) Microproliferations in proliferative diabetic retinopathy and their relationship to the vitreous: corresponding light and electron microscopic studies. Graefes Arch Clin Exp Ophthalmol 223:130–138
Folgar FA, Toth CA, DeCroos FC et al (2012) Assessment of retinal morphology with spectral and time domain OCT in the phase III trials of enzymatic vitreolysis. Invest Ophthalmol Vis Sci 53:7395–7401. doi:10.1167/iovs.12-10379
Gad El Kareem AM, Willikens B, Stassen JM et al (2010) Differential vitreous dye diffusion following microplasmin or plasmin pre-treatment. Curr Eye Res 35:235–241
Gad El Kareem A, Zwinderman AH, Mateo-Montoya A, et al (2013) The vitreous and its retinal interface in ocular health and disease. Ophthalmologica (in press)
Gao BB, Chen X, Timothy N et al (2008) Characterization of the vitreous proteome in diabetes without diabetic retinopathy and diabetes with proliferative diabetic retinopathy. J Proteome Res 7:2516–2525
Hong SW, Jee D (2012) Effect of the honan intraocular pressure reducer to prevent vitreous reflux after intravitreal bevacizumab injection. Eur J Ophthalmol 22:615–619
Hubschman JP, Coffee RE, Bourges JL et al (2010) Experimental model of intravitreal injection techniques. Retina 30:167–173
Johnson MW (2012) Posterior vitreous detachment. Evolution and role in macular disease. Retina 32:S174–S178
Johnson MW (2013) How should we release vitreomacular traction: surgically, pharmacologically, or pneumatically? Am J Ophthalmol 155:203–205.e1. doi:10.1016/j.ajo.2012.10.016
Mojana F, Kozak I, Oster SF et al (2010) Observations by spectral-domain optical coherence tomography combined with simultaneous scanning laser ophthalmoscopy: imaging of the vitreous. Am J Ophthalmol 149:641–650. doi:10.1016/j.ajo.2009.11.016
NasrAllah FP, Jalkh AE, Van Coppenolle F et al (1988) The role of the vitreous in diabetic macular edema. Ophthalmology 95:1335–1339
Ochoa-Contreras E, Delsol-Coronado L, Buitrago ME et al (2000) Induced posterior vitreous detachment by intravitreal sulfur hexafluoride (SF6) injection in patients with nonproliferative diabetic retinopathy. Acta Ophthalmol Scand 78:687–688
Ono R, Kakehashi A, Yamagami H et al (2005) Prospective assessment of proliferative diabetic retinopathy with observations of posterior vitreous detachment. Int Ophthalmol 26:15–19
Rodrigues EB, Meyer CH, Grumann A Jr et al (2007) Tunelled incision to prevent vitreous reflux after intravitreal injection. Am J Ophthalmol 143:1035–1037
Rodrigues EB, Grumann A Jr, Penha FM et al (2011) Effect of needle type and injection technique on pain level and vitreal reflux in intravitreal injection. J Ocul Pharmacol Ther 27:197–203. doi:10.1089/jop.2010.0082
Rodrigues IA, Stangos AN, McHugh DA et al (2013) Intravitreal injection of expansile perfluoropropane (c(3)f(8)) for the treatment of vitreomacular traction. Am J Ophthalmol 155:270–276.e2. doi:10.1016/j.ajo.2012.08.018
Schneider EW, Johnson MW (2011) Emerging nonsurgical methods for the treatment of vitreomacular adhesion: a review. Clin Ophthalmol 5:1151–1165. doi:10.2147/OPTH.S14840
Sebag J (2007) Pharmacologic vitreolysis—premise and promise of the first decade. Retina 29:871–874
Sebag J (2008) Vitreoschisis. Graefes Arch Clin Exp Ophthalmol 246:329–332. doi:10.1007/s00417-007-0743-x
Sebag J, Ansari R, Suh K (2007) Pharmacologic vitreolysis with microplasmin increases vitreous diffusion coefficients. Graefes Arch Clin Exp Ophthalmol 245:576–580
Stalmans P, de Laey C, de Smet M et al (2010) Intravitreal injection of microplasmin for treatment of vitreomacular adhesion: results of a prospective, randomized, sham-controlled phase II trial (the MIVI-IIT trial). Retina 30:1122–1127
Stalmans P, Benz MS, Gandorfer A et al (2012) Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med 367:606–615. doi:10.1056/NEJMoa1110823
Tagawa H, McMeel JW, Furukawa H et al (1986) Role of the vitreous in diabetic retinopathy. 1. Vitreous changes in diabetic retinopathy and in physiologic aging. Ophthalmology 93:596–601
Takahashi M, Trempe CL, Maguire K et al (1981) Vitreoretinal relationship in diabetic retinopathy: a biomicroscopic evaluation. Arch Ophthalmol 99:241–245
Tammewar AM, Bartsch DU, Kozak I et al (2009) Imaging vitreomacular interface abnormalities in the coronal plane by simultaneous combined scanning laser and optical coherence tomography. Br J Ophthalmol 93:366–372
Thresher RJ, Ehrenberg M, Machemer R (1984) Gas-mediated vitreous compression: an experimental alternative to mechanized vitrectomy. Graefes Arch Clin Exp Ophthalmol 221:192–198
Usman Saeed M, Batra R, Qureshi F et al (2011) Reflux of drug during intra-vitreal anti-VEGF therapies. Semin Ophthalmol 26:357–360. doi:10.3109/08820538.2011.588648
Wang Z-LM, Zhang XM, Xu XM et al (2005) PVD following plasmin but not hyaluronidase: implications for combination pharmacologic vitreolysis therapy. Retina 25:38–43
Wang MY, Nguyen D, Hindoyan N et al (2009) Vitreo-papillary adhesion in macular hole and macular pucker. Retina 29:644–650
Zhi-Liang W, Wo-Dong S, Min L et al (2009) Pharmacologic vitreolysis with plasmin and hyaluronidase in diabetic rats. Retina 29:269–274
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Additional information
Compliance with Ethical Requirements
Porf de Smet declares to have received research grants from ThromboGenics and received speaker’s honoraria from ThromboGenics, Inc and Alcon, Inc and is a consultant for ThromboGenics on preclinical studies and development. The author is also a patent holder on the ocular application of ocriplasmin.
Dr. Kuppermann was a consultant and clinical investigator for ISTA Pharmaceuticals and a clinical investigator and is currently a consultant for ThromboGenics and Alcon. He has received speaker’s honoraria from ThromboGenics and Alcon. Dr. Kuppermann has no other relevant disclosures in the field of vitreolysis.
No animal or human studies were carried out by the authors for this article.
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
de Smet, M.D., Kuppermann, B.D. (2014). Pharmacologic Vitreolysis: New Perspectives, Future Directions. In: Girach, A., de Smet, M. (eds) Diseases of the Vitreo-Macular Interface. Essentials in Ophthalmology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-40034-6_12
Download citation
DOI: https://doi.org/10.1007/978-3-642-40034-6_12
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-40033-9
Online ISBN: 978-3-642-40034-6
eBook Packages: MedicineMedicine (R0)